- Home
- BTCT vs TPST Comparison
BTCT vs TPST Comparison
Compare BTCT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTCT | TPST |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 15.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTCT | TPST |
|---|---|---|
| Price | $1.67 | $2.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 99.2K | 76.9K |
| Earning Date | 05-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,427,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.61 | N/A |
| 52 Week Low | $1.26 | $2.75 |
| 52 Week High | $9.90 | $13.65 |
Technical Indicators
Market Signals| Indicator | BTCT | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 27.88 |
| Support Level | $1.26 | $2.80 |
| Resistance Level | $1.83 | $3.04 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 65.62 | 8.29 |
Price Performance
Historical ComparisonAbout BTCT BTC Digital Ltd.
BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.